113 completed, 25 unknown, 23 recruiting, 21 terminated. 118 Phase 2, 64 Phase 3, 27 Phase 1, 6 Not applicable, 3 Phase 4.
Follow Dacarbazine: new trials by email Literature Review of Dacarbazine trials Research Report on Dacarbazine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment Biospecimen Collection, Brentuximab Vedotin, Computed Tomography - Classic Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 23 | 2026-10-01 | 2026-08-20 |
| Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine - Melanoma (Skin) Stage IV | Phase 2 | Recruiting | Sun Yat-sen University | 28 | 2026-10-01 | 2026-09-29 |
| Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL Nivolumab, Doxorubicin Hydrochloride, Vinblastine - Hodgkin Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 15 | 2026-08-19 | 2026-08-31 |
| Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery Sintilimab, Dacarbazine or Temozolomide, Cisplatin - Mucosal Melanoma, PD-L1 Positive | Phase 2 | Recruiting | The First Hospital of Jilin University | 220 | 2026-04-10 | 2026-09-03 |
| A Phase II Trial of LM103 in Advanced Melanoma LM103 TILs Injection, Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin - Advanced Melanoma | Phase 2 | Recruiting | Suzhou BlueHorse Therapeutics Co., Ltd. | 92 | 2025-12-16 | 2026-08-31 |
| Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE) Doxorubicin, Ifosfamide, Dacarbazine - Sarcoma,Soft Tissue | Phase 2 | Recruiting | Swiss Cancer Institute | 24 | 2025-10-27 | 2025-12-30 |
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide) - Melanoma (Skin Cancer), Melanoma Stage IIIB-IV | Phase 2 / Phase 3 | Recruiting | Linnaeus Therapeutics, Inc. | 135 | 2025-08-06 | 2026-04-22 |
| BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma Brentuximab Vedotin, Etoposide, Cyclophosphamide - Hodgkin Lymphoma, Advanced Hodgkin Lymphoma | Phase 2 | Recruiting | University of Miami | 48 | 2025-07-15 | 2025-11-03 |
| Nivo40-AVD for Advanced Classic Hodgkin Lymphoma Nivolumab, Doxorubicin, Vinblastine - Hodgkin Lymphoma, Adult | Phase 2 | Recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | 54 | 2025-04-15 | 2025-11-26 |
| Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma Biospecimen Collection, Computed Tomography, Dacarbazine - Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma | Phase 2 | Recruiting | University of Washington | 125 | 2025-03-06 | 2026-09-09 |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma IMA203, nivolumab plus relatlimab, lifileucel - Melanoma, Cutaneous Malignant, Mucosal Melanoma | Phase 3 | Recruiting | Immatics US, Inc. | 450 | 2025-01-14 | 2026-10-30 |
| A Study of GC101 TIL in Advanced Melanoma GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin - Melanoma | Phase 2 | Recruiting | Shanghai Juncell Therapeutics | 98 | 2024-12-20 | 2026-08-05 |
| Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment Brentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin - Classical Hodgkin Lymphoma, Child | Phase 2 / Phase 3 | Recruiting | Children's Cancer Group, China | 96 | 2024-09-25 | 2026-03-19 |
| A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India Brentuximab Vedotin, Doxorubicin, Vinblastine - Hodgkin Lymphoma | Phase 4 | Recruiting | Takeda | 124 | 2024-08-28 | 2026-02-23 |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) Naporafenib, Dacarbazine, Temozolomide - Advanced or Metastatic NRAS-mutant Melanoma | Phase 3 | Active not recruiting | Erasca, Inc. | 78 | 2024-04-29 | 2026-02-27 |
| A Study of BV-AVD in People With Bulky Hodgkin Lymphoma Brentuximab vedotin, Doxorubicin, Vinblastine - Hodgkin Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2024-04-17 | 2026-04-23 |
| Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - Classic Hodgkin Lymphoma | Phase 2 | Active not recruiting | Northwestern University | 30 | 2024-02-06 | 2026-07-13 |
| PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab - Hodgkin Lymphoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2023-12-14 | 2026-10-06 |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma IDE196, Crizotinib, Pembrolizumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Active not recruiting | IDEAYA Biosciences | 420 | 2023-10-31 | 2026-02-17 |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin - Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1875 | 2023-05-11 | 2026-10-29 |
Showing 20 of 198. Sign in to see all of them.
Melanoma (76) · Hodgkin Disease (56) · Lymphoma (22) · Sarcoma (13) · Neoplasm Metastasis (11) · Leiomyosarcoma (8) · Neoplasms (7) · Uveal Melanoma (7) · Skin Neoplasms (6) · Neuroblastoma (4) · HIV Infections (3) · Recurrence (3) · Sarcoma, Synovial (3) · Hematologic Diseases (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2)
M.D. Anderson Cancer Center (9) · University of Cologne (8) · Bristol-Myers Squibb (7) · National Cancer Institute (NCI) (7) · AstraZeneca (5) · Memorial Sloan Kettering Cancer Center (4) · Merck Sharp & Dohme LLC (4) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Genta Incorporated (3) · German Society for Pediatric Oncology and Hematology GPOH gGmbH (3) · Northwestern University (3) · Philogen S.p.A. (3) · SWOG Cancer Research Network (3) · Seagen Inc. (3) · Takeda (3)
United States (114) · Germany (48) · Italy (42) · United Kingdom (36) · Canada (35) · France (35) · Spain (34) · Netherlands (27) · Australia (25) · Switzerland (22) · Belgium (20) · Poland (18) · China (16) · Czechia (14) · Israel (14)
Andreas Engert, Prof. (4) · Frank Berthold, MD (4) · Agop Y. Bedikian, MD (3) · Anas Younes, MD (3) · Dieter Koerholz, MD (3) · Adil Daud, M.D. (2) · Alessandro M Gianni, MD (2) · Alex F Herrera (2) · Claus Garbe, Prof. M.D. (2) · Evan Hersh, MD (2)
PMID 40135712, PMID 37505794, PMID 24121121, PMID 23509310, PMID 24239220, PMID 27465021, PMID 30010775, PMID 39058968, PMID 39620432, PMID 41074963, PMID 11464889, PMID 11904735, PMID 12101494, PMID 12932669, PMID 15837968, PMID 16051328, PMID 16170182, PMID 16314615, PMID 16446334, PMID 16826357, PMID 17023156, PMID 17443000, PMID 17846017, PMID 18445842, PMID 19001327, PMID 19430405, PMID 20564083, PMID 20572040, PMID 20713848, PMID 20818855, PMID 21079154, PMID 21600759, PMID 21639808, PMID 21639810, PMID 21750549, PMID 21774708, PMID 22028492, PMID 22149921, PMID 22256804, PMID 22371887, PMID 22972589, PMID 23077008, PMID 23182987, PMID 23295794, PMID 23356491, PMID 23386127, PMID 23402397, PMID 23457002, PMID 23735514, PMID 24359243
2004 (3), 2009 (3), 2014 (3), 2023 (3), U10CA032102 (3), P30CA016672 (2), P30CA060553 (2), U10CA180821 (2), 2005 (1), 2008 (1), 2015 (1), 2017 (1), 2018 (1), 2019 (1), M01RR000096 (1)